Retham Technologies Raises $1.5 Million in Seed Funding
Retham Technologies, a company focused on transforming the diagnosis of Heparin induced thrombocytopenia (HIT) through rapid and accurate testing methods, has announced a successful seed funding round. The Wauwatosa, Wisconsin-based firm secured $1.5 million in funding.
Investors and Leadership
The seed funding round was led by Talents Fund, with participation from Golden Angels Investors and Milwaukee Venture Partners. This funding will support Retham Technologies in advancing its diagnostic capabilities and expanding its market reach.
The company is helmed by Steven Visuri, who serves as the CEO, and Anand Padmanabhan, who is the Co-Founder, Chief Scientific Officer, and Chief Medical Officer.
Strategic Use of Funds
While specific plans for the newly raised funds were not detailed, it is expected that the investment will be directed towards enhancing Retham Technologies' testing solutions and possibly expanding its team to support further research and development.
About Retham Technologies
Retham Technologies is committed to improving the speed and accuracy of diagnosing Heparin induced thrombocytopenia, a condition that can complicate the use of the blood-thinning medication heparin. The company's innovative approach aims to provide healthcare professionals with reliable testing methods to better manage patient care.